These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8951694)

  • 41. Triflavin potentiates the antiplatelet activity of platelet activating factor receptor antagonist on activated neutrophil-induced platelet aggregation.
    Lee LW; Peng HC; Ko WC; Hung WC; Su CH; Lin CH; Huang TF; Yen MH; Sheu JR
    Eur J Pharmacol; 1999 Jan; 364(2-3):239-46. PubMed ID: 9932729
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma drug levels compared with DNA incorporation of 3'-azido-3'-deoxythymidine (AZT) in adult cynomolgus (Macaca fascicularis) monkeys.
    Olivero OA; Reddy MK; Pietras SM; Poirier MC
    Exp Biol Med (Maywood); 2001 May; 226(5):446-9. PubMed ID: 11393173
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PAF-induced platelet aggregation ex vivo as a method for monitoring pharmacological activity in healthy volunteers.
    Adamus WS; Heuer H; Meade CJ
    Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):415-20. PubMed ID: 2747341
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dose-dependent agonist and antagonist effects of the platelet-activating factor analogue 1-palmitoyl-2-acetoyl-sn-glycero-3-phosphocholine on B lymphocytes.
    Mazer BD; Toledano B; Saririan M; Bastien Y
    J Allergy Clin Immunol; 1998 Aug; 102(2):231-7. PubMed ID: 9723666
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Platelet-activating factor stimulates secretion of respiratory glycoconjugate from human airways in culture.
    Goswami SK; Ohashi M; Stathas P; Marom ZM
    J Allergy Clin Immunol; 1989 Nov; 84(5 Pt 1):726-34. PubMed ID: 2478607
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
    Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
    J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel class of platelet activating factor (PAF) antagonists. II. Modification of the 2-position of the glycerol backbone of PAF-sulfonamide isosteres.
    Tsuri T; Matsui T; Haga N; Kamata S; Hagishita S; Takahashi K; Kakushi H; Uchida K; Hatakeyama H; Kurosawa A
    Chem Pharm Bull (Tokyo); 1992 Jan; 40(1):85-95. PubMed ID: 1576692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of platelet-activating factor-induced cutaneous edema and erythema in dogs.
    Watanabe M; Osada H; Shimizu S; Goto S; Nagai M; Shirai J; Sasaki K; Shimoda M; Itoh H; Ohmori K
    Am J Vet Res; 2016 Sep; 77(9):969-75. PubMed ID: 27580108
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy.
    Tselepis AD; Goudevenos JA; Tambaki AP; Michalis L; Stroumbis CS; Tsoukatos DC; Elisaf M; Sideris DA
    Cardiovasc Res; 1999 Jul; 43(1):183-91. PubMed ID: 10536703
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
    Komuro Y; Imanishi N; Uchida M; Morooka S
    Mol Pharmacol; 1990 Sep; 38(3):378-84. PubMed ID: 2402227
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between androstenedione-induced myometrial contractions and platelet-activating factor acetylhydrolase in late gestation in pregnant rhesus monkeys.
    Giussani DA; Parks JE; Hough SR; Jenkins SL; Winter JA; Nathanielsz PW
    Biol Reprod; 1997 Jan; 56(1):247-52. PubMed ID: 9002656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A pharmacokinetic/pharmacodynamic model for a platelet activating factor antagonist based on data arising from Phase I studies.
    Evans L; Aarons L; Brearley C
    J Pharm Pharmacol; 2005 Feb; 57(2):183-9. PubMed ID: 15720781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Suppression of PAF-induced bronchoconstriction in the guinea-pig by oxatomide: mechanism of action.
    Nijkamp FP; Folkerts G; Beetens JR; De Clerck F
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Jul; 340(1):111-8. PubMed ID: 2571942
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Separation of the four stereoisomers of a potent inhibitor (L-694,458) of human leukocyte elastase and its determination in human plasma using achiral/chiral chromatography with column switching.
    Zagrobelny J; Matuszewski BK; Kline WF; Vincent SH
    J Pharm Biomed Anal; 1998 Sep; 17(6-7):1057-64. PubMed ID: 9884195
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibodies to platelet-activating factor (PAF) inhibit PAF-induced platelet aggregation.
    Smal MA; Cooney SJ; Baldo BA
    J Lipid Mediat; 1991 Nov; 4(3):333-41. PubMed ID: 1764578
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vivo antiaggregatory action of platelet-activating factor in beagle dogs: role for prostacyclin.
    Hermán F; Magyar K; Filep JG
    Thromb Haemost; 1991 Mar; 65(3):296-9. PubMed ID: 2048053
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nasal allergen challenge generates 1-0-hexadecyl-2-lyso-sn-glycero-3-phosphocholine.
    Shin MH; Averill FJ; Hubbard WC; Chilton FH; Baroody FM; Liu MC; Naclerio RM
    Am J Respir Crit Care Med; 1994 Mar; 149(3 Pt 1):660-6. PubMed ID: 8118633
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development, synthesis, and biological evaluation of (-)-trans-(2S,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3- hydroxypropoxy)-phenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran, a potent orally active platelet-activating factor (PAF) antagonist and its water-soluble prodrug phosphate ester.
    Girotra NN; Biftu T; Ponpipom MM; Acton JJ; Alberts AW; Bach TN; Ball RG; Bugianesi RL; Parsons WH; Chabala JC
    J Med Chem; 1992 Sep; 35(19):3474-82. PubMed ID: 1404229
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Platelet-activating factor (PAF) in male reproductive organs of guinea pigs and rats: effect of androgen on PAF in seminal vesicles.
    Muguruma K; Komatz Y; Ikeda M; Sugimoto T; Saito K
    Biol Reprod; 1993 Feb; 48(2):386-92. PubMed ID: 8439628
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
    Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
    Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.